Drug development for urgent medical needs



IHP Therapeutics is developing IHP-009, a Phase 3 ready new molecule to treat patients hospitalized with COVID-19. Our pipeline programs include novel carbohydrate-based drugs to treat inflammation and the pathologies of infectious diseases.


To improve and save lives through scientific discovery and development of therapeutics.


Our Team

Rinko Ghosh, MS, MBA


Jocelyn Jackson

Acting CFO

Peggy McLaughlin

VP of Clinical Operations

Gabriel Njikang, PhD

Director of CMC Project Mgmt

John Paderi, PhD

Chief Science Officer

Kate Stuart, PhD

 VP of Program Management

Robert Van Gorp

VP of Strategic Sourcing

Board of Directors

Rinko Ghosh, MS, MBA

Vlad Hogenhuis, MD, MBA

John Paderi, PhD

Clinical and Scientific Advisors

Science Student


IHP Therapeutics is building on nearly a century of clinical and basic science research with heparin and related carbohydrate-based compounds. While most widely recognized as an anticoagulant, heparin has numerous activities and heparin-derived compounds hold great promise for treating many different conditions, including infection and inflammation, which are critical for COVID-19. We are developing both novel compounds as well as late clinical-stage drugs like IHP-009, a new chemical entity with an established clinical safety profile. Our goal is to translate the therapeutic potential of these carbohydrate-based compounds into clinically significant benefits for patients.